On September 8, 2025, Johnson & Johnson announced the election of John Morikis to its Board of Directors. Mr. Morikis, a retired executive from The Sherwin-Williams Company, will serve on the Audit Committee and Compensation & Benefits Committee. His previous leadership experience includes roles as Executive Chairman, President, and CEO at Sherwin-Williams, where he led significant strategic transformations and expanded the company's global presence.
Mr. Morikis is recognized for his understanding of global markets and complex supply chains, which Johnson & Johnson believes will be beneficial as the company pursues its healthcare innovation goals. He currently holds positions on the boards of several companies, including United Parcel Service, General Mills, and Whirlpool, and has an educational background in Business Administration and Psychology, along with a master's degree in Business.
linkSep 08, 2025 19:55:25
Johnson & Johnson announced its financial results for the second quarter of 2025, reporting a sales increase of 5.8% to $23.7 billion. The company's earnings per share (EPS) were $2.29, with an adjusted EPS of $2.77. The growth was attributed to strong performance in both its Innovative Medicine and MedTech segments, with notable contributions from oncology and cardiovascular products. The company also made significant advancements in its product pipeline, including approvals and ongoing clinical trials for various treatments.
In response to its strong performance, Johnson & Johnson raised its full-year sales guidance by $2 billion to 5.4% growth at the midpoint, and adjusted its EPS guidance upward by $0.25 to $10.85. The company highlighted operational sales growth in its Innovative Medicine segment of 3.8% and 6.1% in MedTech, driven by key products and favorable foreign exchange impacts. The company continues to focus on its diversified business model and innovative healthcare solutions to drive future growth.
linkJul 16, 2025 08:06:45
Johnson & Johnson has announced the election of Daniel Pinto, President of JPMorgan Chase, to its Board of Directors. The company’s leadership expressed optimism about Pinto's financial expertise and experience in global capital markets, suggesting that his presence will enhance the company’s efforts in advancing healthcare innovation.
Pinto has a long-standing career at JPMorgan Chase, holding various leadership roles and accumulating over three decades of financial experience. He is set to retire from JPMorgan Chase at the end of 2026, but will maintain his position as President until June 30, 2025, after which he will serve as Vice Chairman until his retirement.
linkJun 10, 2025 17:06:51
Johnson & Johnson reported a 2.4% increase in sales for Q1 2025, reaching $21.9 billion, with operational growth at 4.2%. Earnings per share rose significantly to $4.54, influenced by the reversal of special charges. The company highlighted advancements in their product pipeline, including approvals for several treatments and the initiation of a clinical trial for a new robotic system, OTTAVA. Additionally, the company raised its full-year operational sales guidance following the acquisition of Intra-Cellular Therapies.
On the downside, international sales saw a slight decline of 1.8%, and the company faced challenges in its MedTech segment, where growth was impacted by specific product categories. The report also indicated that certain products, like STELARA, negatively affected growth rates in the Innovative Medicine segment. Overall, while the company experienced growth in various areas, there were notable declines in specific segments and regions.
linkApr 15, 2025 08:14:19
Johnson & Johnson has decided to return to the tort system to contest talc claims after the U.S. Bankruptcy Court denied its subsidiary Red River Talc LLC's proposed bankruptcy plan. The company reports that it has won 16 out of 17 ovarian cases over the past 11 years and intends to litigate rather than settle what it describes as meritless claims. The company also plans to reverse approximately $7 billion from previously reserved amounts related to the bankruptcy resolution.
On the negative side, the court's decision has prompted Johnson & Johnson to face ongoing litigation challenges, as it contends that the talc claims are driven by plaintiff lawyers with financial conflicts. The company emphasizes that it will actively fight these claims, asserting that they lack merit and are supported by flawed science. Despite settling 95% of filed mesothelioma lawsuits and resolving other related claims, the company faces a complex legal landscape as it prepares to address every filed case in court.
linkApr 03, 2025 16:43:02
Johnson & Johnson announced a 5.3% increase in fourth-quarter sales, reaching $22.5 billion. The company reported significant operational growth of 6.7% and adjusted operational growth of 5.7%. Noteworthy achievements included advancements in their product pipeline and a strong performance in the U.S. market, which saw a 10% sales increase. The full-year sales also grew by 4.3% to $88.8 billion, with earnings per share (EPS) increasing by 11.3% to $5.79.
On the downside, net earnings for the fourth quarter fell by 17% to $3.43 billion, and diluted EPS decreased by 17.1% to $1.41, impacted by charges related to acquisitions. Adjusted net earnings also declined by 11.1% year-over-year. Additionally, international sales saw a slight decrease, with a reported drop of 0.7% in the fourth quarter. Overall, while the company showed growth in several areas, the decline in net earnings and some international performance metrics raised concerns.
linkJan 22, 2025 06:35:57
Johnson & Johnson reported a sales increase of 5.2% for the third quarter of 2024, reaching $22.5 billion, with operational growth slightly higher at 6.3%. The company made significant advancements in its product pipeline, receiving approvals for key treatments and launching new medical technologies. This reflects a strong commitment to innovation in healthcare, which bodes well for future growth. However, the earnings per share (EPS) fell sharply by 34.3% due to a one-time special charge, and adjusted EPS also decreased by 9%, indicating challenges in profitability despite sales growth.
Additionally, while the company raised its sales guidance for the year, the impact of recent acquisitions, particularly of V-Wave, has affected earnings expectations. The MedTech segment showed solid growth, aided by acquisitions, but other areas faced headwinds. Overall, Johnson & Johnson's performance highlights its strengths in product development and sales while also revealing vulnerabilities in earnings that could concern investors.
linkOct 15, 2024 07:37:20
Johnson & Johnson's subsidiary, Red River Talc LLC, has filed for Chapter 11 bankruptcy to resolve ongoing ovarian cancer claims linked to its talc products. The plan has gained significant backing, with approximately 83% of current claimants in support, allowing for a swift resolution of nearly all pending lawsuits. The company has committed an increased settlement of around $8 billion, which is considered a substantial improvement for claimants compared to potential trial outcomes, where many have not received compensation.
The bankruptcy plan aims to address 99.75% of all related lawsuits, with the remaining cases concerning mesothelioma being handled separately. Despite the legal challenges, Johnson & Johnson maintains that the claims against them lack merit, citing successful defenses in past trials. The company emphasizes its commitment to resolving these issues fairly and equitably, while also highlighting the long-term financial implications of the settlement for all parties involved.
linkSep 20, 2024 16:19:26
Johnson & Johnson has announced the retirement of Dr. Peter Fasolo, who has served as Chief Human Resources Officer for 16 years. His leadership during challenging times, such as the global pandemic and the separation of the consumer health business, has been commendable. Dr. Fasolo leaves behind a legacy of strong leadership and a commitment to employee well-being, recognized by awards like the HR Executive of the Year in 2022.
Kristen Mulholland will succeed Dr. Fasolo, bringing extensive experience from her 19 years at the company. Her previous roles have equipped her with a deep understanding of J&J's operations, and she is expected to continue fostering a positive workplace culture and advancing the company's human capital strategy. The transition is seen as a positive move for maintaining the company's commitment to innovation and employee support.
linkAug 26, 2024 16:26:20
Johnson & Johnson's Q2 2024 reported sales grew 4.3% to $22.4 billion, with adjusted EPS increasing by 10.2%. The company highlighted progress in new product development, raised operational sales guidance due to the Shockwave Medical acquisition, and updated adjusted EPS guidance. Despite a decrease in net earnings, the CEO emphasized a focus on medical innovation, upcoming regulatory milestones, and the integration of recent acquisitions for future growth.
linkJul 17, 2024 08:14:26